Procalcitonin: Is it a predictor of noninvasive positive pressure ventilation necessity in acute chronic obstructive pulmonary disease exacerbation?

Journal of Research in Medical Sciences

Volumn 17, Issue 11, 2012, Pages 1047-1051

  Pazarli, Ahmet Cemal ^a   Koseoglu, Handan Inonu ^a   Doruk, Sibel ^a   Sahin, Semsettin ^a   Etikan, Ilker ^a   Celikel, Serhat ^a   Berktas, Bahadir ^b  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b Education and Research Hospital   (Turkey)

Author keywords

Acute exacerbation; Chronic obstructive pulmonary disease; Noninvasive positive pressure treatment; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ACIDOSIS; ADULT; AGED; ARTERIAL GAS; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOLOGY; HOSPITALIZATION; HUMAN; HYPERCAPNIA; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; POSITIVE END EXPIRATORY PRESSURE; THORAX RADIOGRAPHY; UPPER RESPIRATORY TRACT INFECTION;

EID: 84875083886     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global startegy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2009. Available from: http://www.goldcopd.com. [Last Accessed on 2010 Mar 12].
2. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
3. Voelkel NF, Tuder R. COPD exacerbation. Chest 2000;117:376S-9S.
4. Wedzicha JA. Exacerbations: Etiology and pathophysiologic mechanisms. Chest 2002;121:S136-41S.
5. Maruna, P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res 2000;49:S57-61.
6. Oczenski W R, Fitzgerald D, Schwarz S. Procalcitonin: A new parameter for the diagnosis of bacterial infection in the peri-operative period. Eur J Anaesthesiol 1998;15:202-9.
7. Wrodycki W. Usefulness of plasma procalcitonin (PCT) estimation to diagnose patients in departments of infectious diseases. Przegl Epidemiol 2003;57:211-9.
8. Jimeno A. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 2004;100:2462-9.
9. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
10. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: The evolving clinical challenge. Chest 2012;141:396-405.
11. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, et al. Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;3:9-19.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, european community for steel and coal. Official statement of the European respiratory society. Eur Respir J 1993;16:5-40.
13. Ucan ES, Kocabas A. Turkish Thoracic Society. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease; 2000. Available from: http://www.toraks.org.tr/book. aspx?list=149 and menu=140. [Last accessed on 2010 Mar 20].
14. Garpestad E, Brennan J, Hill NS. Noninvasive ventilation for critical care. Chest 2007;132:711-20.
15. Ece F, Kilickan L, Aytac J, Halim Issever H, Bayindir O. The effect of CRP and procalcitonin levels on the estimation of infection in the COPD patients admitted to ICU with respiratory failure. Turkiye Klinikleri Arch Lung 2009;10:13-21.
16. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003;21:939-43.
17. Tasci{dotless} C, Balkan A, Karadurmus N, Inal S, Kilic S, Ozkan M, et al. The importance of serum procalcitonin levels in patients with chronic obstructive pulmonary disease exacerbations. Turk J Med Sci 2008;38:139-44.
18. Daniels JM, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010;138:1108-15.
19. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131;1058-67.
20. Daubin C, Parienti JJ, Vabret A, Ramakers M, Fradin S, Terzi N, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: A prospective cohort study. BMC Infect Dis 2008;8:145.
21. Rammaert B, Verdier N, Cavestri B, Nseir S. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. Respirology 2009;14:969-74.
22. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;15;174:867-74.